(Q35565133)

English

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

scientific article published on 14 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ethinylestradiol/levonorgestrel

1 reference

based on heuristic

inferred from title

bioavailability

1 reference

based on heuristic

inferred from title

0 references

author name string

Christoph Kapitza

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Leszek Nosek

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Lene Jensen

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Helle Hartvig

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Christine B Jensen

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Anne Flint

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

publication date

14 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

497-504

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Potential of liraglutide in the treatment of patients with type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

26 September 2018

Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418331

26 September 2018

Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/25475122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive

1 reference

https://pubmed.ncbi.nlm.nih.gov/25475122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hy's law: predicting serious hepatotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25475122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://pubmed.ncbi.nlm.nih.gov/25475122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/25475122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/JCPH.443

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35565133&oldid=1939841832"